FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310125639> ?p ?o ?g. }

• W4310125639 endingPage "3340" @default.
• W4310125639 startingPage "3338" @default.
• W4310125639 abstract "Background: Leukemia-cell-stroma interactions are an attractive therapy target in AML. The CXC chemokine receptor 4 (CXCR4) and its ligand CXCL12 (SDF-1) are expressed and secreted by myeloid leukemia blasts and play an essential role in the migration, homing, differentiation, proliferation, and retention of myeloid blasts within the protective bone marrow (BM) niche. The high-affinity CXCR4 antagonist BL-8040 is directly toxic for AML blasts and interrupts the interaction between blasts and the protective BM microenvironment. Objective: The aim of this clinical trial was to evaluate the impact of BL-8040 in combination with standard consolidation therapy on relapse free survival (RFS) in patients with acute myeloid leukemia (AML) in first complete remission (CR, CRp, CRi). Methods: Adult patients ≥ 18 years with documented 1st CR/CRi/CRp, after induction therapy with cytarabine and an anthracycline, and not scheduled for allogeneic stem cell transplantation were randomized in a 1:1 ratio to receive two cycles (≥ 60 years) or three cycles (<60 years) of high-dose cytarabine plus BL-8040 or placebo as consolidation therapy. The dosage of cytarabine was 1g/m² per dose for subjects older than 60 years and 3 g/m² per dose for subjects younger than 60 years. Results: Between November 2015 and November 2019, 134 patients of the originally planned number of 202 were recruited at 29 trial sites, 6 patients violated inclusion and/or exclusion criteria and were excluded. Considering the results of the interim analysis, the data monitoring committee recommended to stop recruitment. Thus, no further patients were enrolled. One hundred and twenty-eight patients were randomized (63 placebo; 65 BL-8040). Baseline characteristics were balanced between treatment arms: median age 61 vs 63 years; 2010 ELN favorable or intermediate-risk 95% vs 98%; CXCR4 expression 38% vs 30% in the BL-8040 and standard arm, respectively. Overall median follow-up time was 25.4 months. Median RFS was similar between arms 10.3 months [95% CI 8.0,12.0] for the BL-8040 arm and 11.5 months [95% CI 8.6,24.1] for the placebo arm (two-sided p=0.98 by log-rank test).The median OS was not reached at the time point of the analysis. Intention to treat (ITT) analyses revealed no difference between placebo and BL-8040, neither for the total cohort, nor for the subset of patients with expression of CXCR4 with respect to RFS (Hazard ratio (HR) 1.0, 95% CI 0.7,1.6, p =0.9, and HR 0.9, 95% CI 0.1,2.9, p =0.9,respectively) or overall survival (OS; HR 1.1, 95% CI 0.6,2.0, p = 0.8, and HR 2.5, 95% CI 0.4,13.8, p = 0.3, respectively). Regarding safety endpoints, overall, 739 and 576 adverse events were documented in the BL-8040 and placebo arm, respectively. Serious adverse events were similar between therapies. Conclusion: The addition of BL-8040 to intensive consolidation therapy did not improve RFS or OS. Although more side effects were noted, no differences in serious adverse events were observed." @default.
• W4310125639 created "2022-11-30" @default.
• W4310125639 creator A5000841982 @default.
• W4310125639 creator A5008552757 @default.
• W4310125639 creator A5009950958 @default.
• W4310125639 creator A5011054267 @default.
• W4310125639 creator A5015464116 @default.
• W4310125639 creator A5016177326 @default.
• W4310125639 creator A5016869284 @default.
• W4310125639 creator A5022616874 @default.
• W4310125639 creator A5022716339 @default.
• W4310125639 creator A5025524401 @default.
• W4310125639 creator A5026359397 @default.
• W4310125639 creator A5030475043 @default.
• W4310125639 creator A5033409292 @default.
• W4310125639 creator A5035426042 @default.
• W4310125639 creator A5035709794 @default.
• W4310125639 creator A5036464133 @default.
• W4310125639 creator A5037612992 @default.
• W4310125639 creator A5038634249 @default.
• W4310125639 creator A5039600580 @default.
• W4310125639 creator A5042854645 @default.
• W4310125639 creator A5042951988 @default.
• W4310125639 creator A5051197527 @default.
• W4310125639 creator A5052465396 @default.
• W4310125639 creator A5052619425 @default.
• W4310125639 creator A5053337540 @default.
• W4310125639 creator A5053949970 @default.
• W4310125639 creator A5053957693 @default.
• W4310125639 creator A5056379122 @default.
• W4310125639 creator A5056684984 @default.
• W4310125639 creator A5057074442 @default.
• W4310125639 creator A5059688227 @default.
• W4310125639 creator A5060270110 @default.
• W4310125639 creator A5063051642 @default.
• W4310125639 creator A5064137049 @default.
• W4310125639 creator A5065134818 @default.
• W4310125639 creator A5068697219 @default.
• W4310125639 creator A5070309355 @default.
• W4310125639 creator A5073263131 @default.
• W4310125639 creator A5077205301 @default.
• W4310125639 creator A5079124367 @default.
• W4310125639 creator A5079338911 @default.
• W4310125639 creator A5080373966 @default.
• W4310125639 creator A5081277564 @default.
• W4310125639 creator A5082589698 @default.
• W4310125639 creator A5083170898 @default.
• W4310125639 creator A5083461984 @default.
• W4310125639 creator A5083561268 @default.
• W4310125639 creator A5083643730 @default.
• W4310125639 creator A5084079017 @default.
• W4310125639 creator A5085192155 @default.
• W4310125639 creator A5086016311 @default.
• W4310125639 creator A5087351196 @default.
• W4310125639 creator A5088570536 @default.
• W4310125639 date "2022-11-15" @default.
• W4310125639 modified "2023-10-14" @default.
• W4310125639 title "Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups" @default.
• W4310125639 doi "https://doi.org/10.1182/blood-2022-166748" @default.
• W4310125639 hasPublicationYear "2022" @default.
• W4310125639 type Work @default.
• W4310125639 citedByCount "0" @default.
• W4310125639 crossrefType "journal-article" @default.
• W4310125639 hasAuthorship W4310125639A5000841982 @default.
• W4310125639 hasAuthorship W4310125639A5008552757 @default.
• W4310125639 hasAuthorship W4310125639A5009950958 @default.
• W4310125639 hasAuthorship W4310125639A5011054267 @default.
• W4310125639 hasAuthorship W4310125639A5015464116 @default.
• W4310125639 hasAuthorship W4310125639A5016177326 @default.
• W4310125639 hasAuthorship W4310125639A5016869284 @default.
• W4310125639 hasAuthorship W4310125639A5022616874 @default.
• W4310125639 hasAuthorship W4310125639A5022716339 @default.
• W4310125639 hasAuthorship W4310125639A5025524401 @default.
• W4310125639 hasAuthorship W4310125639A5026359397 @default.
• W4310125639 hasAuthorship W4310125639A5030475043 @default.
• W4310125639 hasAuthorship W4310125639A5033409292 @default.
• W4310125639 hasAuthorship W4310125639A5035426042 @default.
• W4310125639 hasAuthorship W4310125639A5035709794 @default.
• W4310125639 hasAuthorship W4310125639A5036464133 @default.
• W4310125639 hasAuthorship W4310125639A5037612992 @default.
• W4310125639 hasAuthorship W4310125639A5038634249 @default.
• W4310125639 hasAuthorship W4310125639A5039600580 @default.
• W4310125639 hasAuthorship W4310125639A5042854645 @default.
• W4310125639 hasAuthorship W4310125639A5042951988 @default.
• W4310125639 hasAuthorship W4310125639A5051197527 @default.
• W4310125639 hasAuthorship W4310125639A5052465396 @default.
• W4310125639 hasAuthorship W4310125639A5052619425 @default.
• W4310125639 hasAuthorship W4310125639A5053337540 @default.
• W4310125639 hasAuthorship W4310125639A5053949970 @default.
• W4310125639 hasAuthorship W4310125639A5053957693 @default.
• W4310125639 hasAuthorship W4310125639A5056379122 @default.
• W4310125639 hasAuthorship W4310125639A5056684984 @default.
• W4310125639 hasAuthorship W4310125639A5057074442 @default.
• W4310125639 hasAuthorship W4310125639A5059688227 @default.
• W4310125639 hasAuthorship W4310125639A5060270110 @default.
• W4310125639 hasAuthorship W4310125639A5063051642 @default.
• W4310125639 hasAuthorship W4310125639A5064137049 @default.
• W4310125639 hasAuthorship W4310125639A5065134818 @default.

• next